VVT Med recently shared that the first group of patients in Italy has been treated with the ScleroSafe system. The patients were treated by Luca Palombi and his team, in collaboration with VVT Med’s local distributor, Uber Ros, at Fondazione Villa Salus Hospital in Venice, Italy.
A company press release notes that this latest development marks a milestone in VVT Med’s continued European expansion and reflects physician interest in office-based, minimally invasive vein treatment solutions.
“We were pleased to be the first centre in Italy to treat patients with the ScleroSafe system,” said Palombi. “Treating our first patients with the ScleroSafe system demonstrated a distinctly different approach to sclerotherapy: precise, minimally invasive venous procedures while enhancing the overall treatment experience for both physicians and patients.”
“We are encouraged by the growing interest in ScleroSafe among leading vein specialists in Europe,” said Erez Tetro, CEO of VVT Med. “Italy is an important market for advanced venous care, and we extend our sincere thanks to our valued local distributor, Uber Ros SpA, for their outstanding support in achieving this milestone.”
ScleroSafe is designed to enable controlled sclerosant delivery with simultaneous blood aspiration, supporting targeted interaction with the vein wall while eliminating the need for thermal energy or tumescent anaesthesia. According to VVT Med, the technology provides physicians with an efficient, office-based treatment option across a broad range of vein diameters.
